Cell & Gene Therapy Answers: Addressing Complex Analytical Needs with ddPCR/qPCR

As the rate of cell and gene therapy development increases, Labcorp Drug Development has continued to invest in the technology, capacity and expertise globally to support the evolving and complex analytical needs of our clients. We recently spoke with Hazel Staton, Lead Scientist, BioPharm CMC at Labcorp Drug Development, to learn about droplet digital PCR (ddPCR), how it compares to qPCR, and where the technology can support work in Chemistry, Manufacturing and Control (CMC), preclinical biodistribution and a range of clinical applications (shedding, tracking, adventitious agent detection and the testing of replication competent viruses) to advance complex cell and gene therapies.